{
	"kihkd6kzText": "Bri<span class=\"_ _1\"></span>ntel<span class=\"_ _1\"></span>lix<span class=\"_ _1\"></span>® del<span class=\"_ _1\"></span>iv<span class=\"_ _1\"></span>ers ef<span class=\"_ _4\"></span>fec<span class=\"_ _4\"></span>tiv<span class=\"_ _1\"></span>e and s<span class=\"_ _1\"></span>us<span class=\"_ _4\"></span>tai<span class=\"_ _1\"></span>ned re<span class=\"_ _1\"></span>lief <br><span class=\"ls20 ws29\">fr<span class=\"_ _0\"></span>om symptoms of<span class=\"_ _4\"></span> MDD<span class=\"_ _1\"></span>*<span class=\"fs3 ls1e ws26 v1\">1-3</span></span>",
	"kihkd6l0Text": "Study Design",
	"kihkd6l1Text": "The shor<span class=\"_ _1\"></span>t-term efficacy of<span class=\"_\"> </span> Brintellix® is maintained with continuous <br>treatment over 52 weeks*<span class=\"fs5 v2\">3</span>",
	"kihkd6l2Text": "MADRS total score",
	"kihkd6l3Text": "Study week",
	"kihkd6l4Text": "Brintellix® 5 – 20 mg/day (n=1230)",
	"kihkd6l5Text": "Acute<span class=\"_ _4d\"> </span>Open-label extension",
	"kihkd6l6Text": "Efficacy without ",
	"kihkd6l7Text": "compromising ",
	"kihkd6l8Text": "tolerability**",
	"kihkd6l9Text": "Score",
	"kihkd6laText": "Baseline I",
	"kihkd6lbText": "Baseline II",
	"kihkd6lcText": "W<span class=\"_ _0\"></span>eek 52",
	"Brintellix_254655a6fc": "<span style=\"font-family: &quot;15_VDWFON+AvenirNextLTPro-Demi&quot;; color: rgb(255, 255, 255); line-height: 1.3;\"><font style=\"font-size: 17px;\">\nMean scores for efficacy endpoints in the total population treated with vortioxetine\n<br style=\"\">5-20 mg/day during both the short-term, fixed-dose lead-in studies and the 52-week,\n<br>flexible-dose extension studies.\n</font></span>",
	"Brintellix_256fa853f9": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(100, 94, 94);\"><font style=\"font-size: 14px;\">\nBaseline 1\n</font></span>",
	"Brintellix_25fc86ccbd": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(100, 94, 94);\"><font style=\"font-size: 14px;\">\nBaseline II\n</font></span>",
	"Brintellix_25e52983f1": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(100, 94, 94);\"><font style=\"font-size: 14px;\">\nWeek 52 (OC)\n</font></span>",
	"Brintellix_255fa88ed4": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(100, 94, 94);\"><font style=\"font-size: 14px;\">\nWeek 52 (LOCF)\n</font></span>",
	"Brintellix_25d0c29b59": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 3.2;display:inline-block;\">\nMADRS total score\nHAM-A total score\nCGI-S score\n</font>",
	"Brintellix_25ae69edd4": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 3.2;display:inline-block;\"><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">32.2 ± 4.2&nbsp;</span></div><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">20.1 ± 6.2&nbsp;</span></div><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">4.67 ± 0.67&nbsp;</span></div></font>",
	"Brintellix_25ecfa3670": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 3.2;display:inline-block;\"><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">17.1 ± 10.2&nbsp;</span></div><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">11.3 ± 69&nbsp;</span></div><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">3.11 ± 1.20</span></div></font>",
	"Brintellix_25211c1377": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 3.2;display:inline-block;\"><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">7.6 ± 8.2&nbsp;</span></div><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">6.0 ± 6.0&nbsp;</span></div><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">1.94 ± 1.08&nbsp;</span></div></font>",
	"Brintellix_251d0ad03b": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 3.2;display:inline-block;\"><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">10.3 ± 9.9&nbsp;</span></div><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">7.5 ± 67&nbsp;</span></div><div style=\"text-align: center;\"><span style=\"background-color: transparent;\">2.27 ± 1.26&nbsp;</span></div></font>",
	"Brintellix_25652fe32b": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 1.3;display:inline-block;\">\nBaseline 1, start of treatment in the lead-in study; Baseline II, start of treatment in the extension study;\n<br>CGI-S, Clinical Global Impressions-Severity of Illness; HAM-A, Hamilton Anxiety Rating Scale; LOCF,\n<br>last observation carried forward; MADRS, Montgomery- Asberg Depression Rating Scale; OC,\n<br>observed cases.\n</font>",
	"Brintellix_2528010161": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 1.3;display:inline-block;\">\nAt week 52, the total response rate was 75.4% (n=916/1215, LOCF) and the total remission rate<br>was 60.7% (n=738/1215, LOCF).\n</font>",
	"Brintellix_256a3f5f26": "<span style=\"color: rgb(77, 127, 134); font-family: '15_VDWFON+AvenirNextLTPro-Demi';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_2541d92f2f": "<font style=\"font-size: 15px; font-family: &quot;3_BNJCUB+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1.7; display: inline-block;\"><b style=\"\">\n1.</b> Katona C et al. Int Clin Pyschopharmacol 2012;27:215-223.\n<br><b>2.</b> Alvarez E et al. Int J Neuropsychopharmacol. 2012;15:589-600.\n<br><b>3.</b> Vieta E et al. Eur Neuropsychopharmacol 2017;27:877-884.\n</font>",
	"Brintellix_25928725fa": "",
	"Brintellix_25e23ff022": "",
	"Brintellix_25ffe1178f": "",
	"Brintellix_25c41db5d0": "<font style=\"font-size: 14.5px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 1.3;display:inline-block;\">\nBrintellix<sup>®</sup> 5 – 20 mg/day (n=1230)\n</font>",
	"Brintellix_25ed72a096": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(77, 127, 134);\"><font style=\"font-size: 15px;\">\nMADRS total score\n</font></span>",
	"Brintellix_2583a73a0f": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(77, 127, 134);\"><font style=\"font-size: 15px;\">\nStudy week\n</font></span>",
	"Brintellix_252422183c": "<font style=\"font-size: 11.5px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 1.3;display:inline-block;\">\n<p style=\"margin-bottom: 1px;margin-top: 5px;\">*As assessed by MADRS.</p>\n<p style=\"margin-bottom: 1px;margin-top: 5px;\">Mean MADRS total scores for patients previously treated with Brintellix<sup>®</sup> 5–20 mg/day in six-to-eight week randomised controlled trials <br>who continued treatment in an open-label extension study. Patient-level data were pooled from five long-term (52-week), open-label <br>extension studies of MDD. Only patients who were treated with Brintellix<sup>®</sup> at an approved therapeutic dose (between 5 and 20 mg/day) <br>and who completed the lead-in randomised, double-blind, placebo-controlled, six-to-eight week Brintellix<sup>®</sup> studies were included.</p>\n<p style=\"margin-bottom: 1px;margin-top: 5px;\">**Brintellix<sup>®</sup> does not exhibit many of the side effects typical of SSRIs and SNRIs including sexual dysfunction and weight gain.5—8 <br>Side effects associated with Brintellix<sup>®</sup> were compared with those of the SSRIs escitalopram and paroxetine and with those of the SNRI <br>venlafaxine. For the 20 mg/day dose, an increase in treatment-emergent sexual dysfunction was seen compared to placebo. Please refer&nbsp;to the full Summary of Product Characteristics or Prescribing Information for further information on safety and tolerability.</p>\n</font>",
	"Brintellix_2501faeac9": "",
	"Brintellix_25ed802942": "",
	"Brintellix_252b24e914": "",
	"Brintellix_2596faf94c": "Text",
	"Brintellix_252311c82f": "Text",
	"Brintellix_25a0a99aad": "Text",
	"Brintellix_25f38cf700": "Text",
	"Brintellix_259aba8324": "Text",
	"Brintellix_254b053db7": "Text",
	"Brintellix_25b37ea323": "<span style=\"font-family: &quot;3_BNJCUB+AvenirNextLTPro-Regular&quot;; color: #fff; line-height: 1;\"><div style=\"text-align: center;\"><font style=\"font-size: 16px;\">Acute</font></div>\n\t</span>",
	"Brintellix_25cff9be13": "<span style=\"font-family: &quot;3_BNJCUB+AvenirNextLTPro-Regular&quot;; color: #fff; line-height: 1;\"><div style=\"text-align: center;\"><font style=\"font-size: 16px;\">Open-label extension</font></div>\n\t</span>",
	"Brintellix_25fdcca958": "<div style=\"font-family: serif;font-family: '2_VDWFON+AvenirNextLTPro-Demi';font-size: 13px;background-color: #e5f0f2;box-sizing: border-box;color: #4d7f86;\">\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">MADRS 10</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Physical symptoms</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Remission</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Relapse prevention</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Short term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;color: #fff;background: rgb(233,90,0);background: linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);background: -webkit-linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);\">Long term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Meta-analysis</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 4px 12px 3px;line-height:1.3;background-color: #e5f0f2;\">Suboptimal responses<br>to SSRI/SNRI</div>\n</div>",
	"Brintellix_254a8e6884": "Text"
}
